Immunization in the adult immunocompromised host

Autoimmunity Reviews

Volumn 11, Issue 3, 2012, Pages 212-218

  Löbermann, Micha ^a   Boršo, Denise ^a   Hilgendorf, Inken ^a   Fritzsche, Carlos ^a   Zettl, Uwe K ^a   Reisinger, Emil C ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Antibody response; Immunosuppression; Protection; Vaccination

Indexed keywords

AZATHIOPRINE; CHOLERA VACCINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOSTATIC AGENT; DOXORUBICIN; GAMMA INTERFERON; GLUCOCORTICOID; HEPATITIS B VACCINE; IMMUNOPHILIN; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; LIVE VACCINE; MEASLES VACCINE; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PNEUMOCOCCUS VACCINE; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; RUBELLA VACCINE; TACROLIMUS; TUMOR NECROSIS FACTOR; VARICELLA ZOSTER VACCINE; VINCRISTINE; YELLOW FEVER VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ASPLENIA; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CD4 LYMPHOCYTE COUNT; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; CONGENITAL IMMUNODEFICIENCY; DIABETES MELLITUS; DISEASE TRANSMISSION; DRUG MECHANISM; ENTERITIS; GENETIC PREDISPOSITION; GRAFT RECIPIENT; GRAFT REJECTION; GUILLAIN BARRE SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNE MEDIATED INFLAMMATORY DISEASE; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RATE; KIDNEY GRAFT; LIVER FAILURE; MEASLES; MULTIPLE SCLEROSIS; MUMPS; NEOPLASM; NONHODGKIN LYMPHOMA; ORGAN TRANSPLANTATION; PRACTICE GUIDELINE; PSORIASIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RUBELLA; SEASONAL INFLUENZA; SECONDARY INFECTION; SEROLOGY; SEVERE COMBINED IMMUNODEFICIENCY; SEXUALLY TRANSMITTED DISEASE; SPLENECTOMY; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; WART VIRUS;

AUTOIMMUNE DISEASES; BACTERIAL VACCINES; HIV INFECTIONS; HUMANS; IMMUNIZATION; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFECTION; INFECTION CONTROL; MULTIPLE SCLEROSIS; PRACTICE GUIDELINES AS TOPIC; RISK; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 84855944875     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.05.015     Document Type: Review

References (101)

1. van Staa T.P., Leufkens H.G., Abenhaim L., Begaud B., Zhang B., Cooper C. Use of oral corticosteroids in the United Kingdom. QJM 2000, 93(2):105-111.
2. Wolfe R.A., Merion R.M., Roys E.C., Port F.K. Trends in organ donation and transplantation in the United States, 1998-2007. Am J Transplant 2009, 9(4 Pt 2):869-878.
3. Kuek A., Hazleman B.L., Ostor A.J. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007, 83(978):251-260.
4. Rahier J.F., Moutschen M., Van Gompel A., Van Ranst M., Louis E., Segaert S., et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010, 49(10):1815-1827.
5. Stuck A.E., Minder C.E., Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989, 11(6):954-963.
6. Salliot C., Gossec L., Ruyssen-Witrand A., Luc M., Duclos M., Guignard S., et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007, 46(2):327-334.
7. Salemi S., D'Amelio R. Could autoimmunity be induced by vaccination?. Int Rev Immunol 2010, 29(3):247-269.
8. Salemi S., D'Amelio R. Are anti-infectious vaccinations safe and effective in patients with autoimmunity?. Int Rev Immunol 2010, 29(3):270-314.
9. Loebermann M., Winkelmann A., Reisinger E.C., Zettl U.K. Vaccination and multiple sclerosis. Nervenarzt 2010, 81(2):181-193.
10. Bengtsson C., Kapetanovic M.C., Kallberg H., Sverdrup B., Nordmark B., Klareskog L., et al. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis 2010, 69(10):1831-1833.
11. O'Neill S.G., Isenberg D.A. Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety. Lupus 2006, 15(11):778-783.
12. Holvast B., Huckriede A., Kallenberg C.G., Bijl M. Influenza vaccination in systemic lupus erythematosus: safe and protective?. Autoimmun Rev 2007, 6(5):300-305.
13. van Assen S., Holvast A., Benne C.A., Posthumus M.D., van Leeuwen M.A., Voskuyl A.E., et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62(1):75-81.
14. Kuruma K.A., Borba E.F., Lopes M.H., de Carvalho J.F., Bonfa E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 2007, 16(5):350-354.
15. Aubert C., Vaudaux B., Bart P.A., Universite de L. Immunization guidelines regarding patients with a chronic disease. Rev Med Suisse 2010, 6(245):798-803.
16. Kroger A.T., Atkinson W.L., Marcuse E.K., Pickering L.K., Kroger A.T., Atkinson W.L., et al. Advisory Committee on Immunization Practices Centers for Disease C, Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55:1-48. (RR-15).
17. Rubbert-Roth A. [Vaccination in adult rheumatology]. Z Rheumatol 2007 Mar;66(2):102-10.
18. STIKO Hinweise zu Impfungen für Patienten mit Immundefizienz. Epidemiol Bull 2005, 39:353-364. 2005.
19. Zimmerman RK, Middleton DB. Vaccines for persons at high risk, 2007. J Fam Pract 2007 Feb;56(2 Suppl Vaccines):S104-S112.
20. Lahood N., Emerson S.S., Kumar P., Sorensen R.U. Antibody levels and response to pneumococcal vaccine in steroid-dependent asthma. Ann Allergy 1993, 70(4):289-294.
21. Wallin L., Quintilio W., Locatelli F., Cassel A., Silva M.B., Skare T.L. Safety and efficiency of influenza vaccination in systemic lupus erythematosus patients. Acta Reumatol Port 2009, 34(3):498-502.
22. Staples J.E., Gershman M., Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 30(59):1-27. Centers for Disease C, Prevention, (RR-7).
23. Evison J., Farese S., Seitz M., Uehlinger D.E., Furrer H., Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009, 48(10):1402-1412.
24. Smith K.G., Isbel N.M., Catton M.G., Leydon J.A., Becker G.J., Walker R.G. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998, 13(1):160-164.
25. Keshtkar-Jahromi M., Argani H., Rahnavardi M., Mirchi E., Atabak S., Tara S.A., et al. Antibody response to influenza immunization in kidney transplant recipients receiving either azathioprine or mycophenolate: a controlled trial. Am J Nephrol 2008, 28(4):654-660.
26. Salles M.J., Sens Y.A., Boas L.S., Machado C.M. Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs. Clin Transplant 2010, 24(1):E17-E23.
27. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9(8):493-504.
28. Bingham C.O., Looney R.J., Deodhar A., Halsey N., Greenwald M., Codding C., et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010, 62(1):64-74.
29. Enke B.U., Bokenkamp A., Offner G., Bartmann P., Brodehl J. Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients. Transplantation 1997, 64(2):237-241.
30. Birdwell K.A., Ikizler M.R., Sannella E.C., Wang L., Byrne D.W., Ikizler T.A., et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis 2009, 54(1):112-121.
31. WHO. Priority interventions: HIV/AIDS prevention, treatment and care in the health sector - 2010. Volume 2.0 Geneva: WHO Press, 2010.
32. Spradling P.R., Richardson J.T., Buchacz K., Moorman A.C., Brooks J.T. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007. J Viral Hepat 2010, 17(12):879-886. the HIVOSI.
33. Gupta S., Singh S. Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India. BMC Infect Dis 2010, 10:53.
34. Kim H.N., Harrington R.D., Crane H.M., Dhanireddy S., Dellit T.H., Spach D.H. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS 2009, 20(9):595-600.
35. van den Berg R., van Hoogstraten I., van Agtmael M. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev 2009, 11(3):157-164.
36. Landrum M.L., Huppler Hullsiek K., Ganesan A., Weintrob A.C., Crum-Cianflone N.F., Barthel R.V., et al. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine 2009, 27(34):4731-4738.
37. EACS Guidelines: clinical management and treatment of HIV infected adults in Europe 2009, EACS, European AIDS Clinical Society, Paris, Available online: http://www.europeanaidsclinicalsociety.org/guidelinespdf/EACS-EuroGuidelines_FullVersion.pdf.
38. Aberg J.A., Kaplan J.E., Libman H., Emmanuel P., Anderson J.R., Stone V.E., et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009, 49(5):651-681.
39. Keller D.W., Breiman R.F. Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Clin Infect Dis 1995, 21(Suppl 1):S77-S83.
40. Dworkin M.S., Ward J.W., Hanson D.L., Jones J.L., Kaplan J.E. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001, 32(5):794-800.
41. Redd S.C., Rutherford G.W., Sande M.A., Lifson A.R., Hadley W.K., Facklam R.R., et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990, 162(5):1012-1017.
42. Heffernan R.T., Barrett N.L., Gallagher K.M., Hadler J.L., Harrison L.H., Reingold A.L., et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 15 2005, 191(12):2038-2045.
43. CDC. Recommendations of the Immunization Practices Advisory Committee: pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 1989 Feb 10;38(5):64-8, 73-6.
44. Geretti A.M., Brook G., Cameron C., Chadwick D., Heyderman R.S., MacMahon E., et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008, 9(10):795-848.
45. French N., Nakiyingi J., Carpenter L.M., Lugada E., Watera C., Moi K., et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000, 355(9221):2106-2111.
46. French N., Gordon S.B., Mwalukomo T., White S.A., Mwafulirwa G., Longwe H., et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010, 362(9):812-822.
47. Piketty C., Darragh T.M., Da Costa M., Bruneval P., Heard I., Kazatchkine M.D., et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003, 138(6):453-459.
48. Wilkin T., Lee J.Y., Lensing S.Y., Stier E.A., Goldstone S.E., Berry J.M., et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010, 202(8):1246-1253.
49. Alavian S.M., Tabatabaei S.V. The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: a meta-analysis of current literature. Vaccine 2010, 28(22):3773-3777.
50. Pozzilli P., Gale E.A., Visalli N., Baroni M., Crovari P., Frighi V., et al. The immune response to influenza vaccination in diabetic patients. Diabetologia 1986, 29(12):850-854.
51. Colquhoun A.J., Nicholson K.G., Botha J.L., Raymond N.T. Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect 1997, 119(3):335-341.
52. Looijmans-Van den Akker I., Verheij T.J., Buskens E., Nichol K.L., Rutten G.E., Hak E. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. Diabetes Care 2006, 29(8):1771-1776.
53. Girndt M., Pietsch M., Kohler H. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am J Kidney Dis 1995, 26(3):454-460.
54. Litjens N.H., Huisman M., van den Dorpel M., Betjes M.G. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J Am Soc Nephrol 2008, 19(8):1483-1490.
55. Edey M., Barraclough K., Johnson D.W. Review article: hepatitis B and dialysis. Nephrology (Carlton) 2010, 15(2):137-145.
56. Tsouchnikas I., Dounousi E., Xanthopoulou K., Papakonstantinou S., Thomoglou V., Tsakiris D. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 2007, 68(4):228-234.
57. Ghassemi S., Garcia-Tsao G. Prevention and treatment of infections in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007, 21(1):77-93.
58. Tandon P., Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008, 28(1):26-42.
59. Gaeta G.B., Pariani E., Amendola A., Brancaccio G., Cuomo G., Stornaiuolo G., et al. Influenza vaccination in patients with cirrhosis and in liver transplant recipients. Vaccine 2009, 27(25-26):3373-3375.
60. Loulergue P., Pol S., Mallet V., Sogni P., Launay O., Group G. Why actively promote vaccination in patients with cirrhosis?. J Clin Virol 2009, 46(3):206-209.
61. CDC Recommended adult immunization schedule-United States, 2010. MMWR Morb Mortal Wkly Rep 2010, 59(1):1-4.
62. Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009, 9(3):185-194.
63. Grubeck-Loebenstein B. Fading immune protection in old age: vaccination in the elderly. J Comp Pathol 2010, 142(Suppl 1):S116-S119.
64. Ongradi J., Kovesdi V. Factors that may impact on immunosenescence: an appraisal. Immun Ageing 2010, 7:7.
65. Olander R.M., Auranen K., Harkanen T., Leino T. High tetanus and diphtheria antitoxin concentrations in Finnish adults-time for new booster recommendations?. Vaccine 2009, 27(39):5295-5298.
66. Van der Wielen M., Van Damme P., Chlibek R., Smetana J., von Sonnenburg F. Hepatitis A/B vaccination of adults over 40years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine 2006, 24(26):5509-5515.
67. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24(8):1159-1169.
68. Vila-Corcoles A. Advances in pneumococcal vaccines: what are the advantages for the elderly?. Drugs Aging 2007, 24(10):791-800.
69. Ridda I., Macintyre C.R., Lindley R., Gao Z., Sullivan J.S., Yuan F.F., et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 2009, 27(10):1628-1636.
70. Weinberger B., Keller M., Fischer K.H., Stiasny K., Neuner C., Heinz F.X., et al. Decreased antibody titers and booster responses in tick-borne encephalitis vaccines aged 50-90years. Vaccine 2010, 28(20):3511-3515.
71. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352(22):2271-2284.
72. Sanford M., Keating G.M. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010, 27(2):159-176.
73. NACI Statement on the recommended use of herpes zoster vaccine. Can Commun Dis Rep 2010, 36:1-19.
74. STIKO Empfehlungen der Standigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2010. Epidemiol Bull 2010, 30:279-298.
75. Scharenberg A.M., Hannibal M.C., Torgerson T., Ochs H.D., Rawlings D.J. Common variable immune deficiency overview 1993, Online at: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=cvid.
76. Melles D.C., de Marie S. Prevention of infections in hyposplenic and asplenic patients: an update. Neth J Med 2004, 62(2):45-52.
77. Arrowood J.R., Hayney M.S. Immunization recommendations for adults with cancer. Ann Pharmacother 2002, 36(7-8):1219-1229.
78. Melcher L. Recommendations for influenza and pneumococcal vaccinations in people receiving chemotherapy. Clin Oncol (R Coll Radiol) 2005, 17(1):12-15.
79. Sinisalo M., Aittoniemi J., Oivanen P., Kayhty H., Olander R.M., Vilpo J. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol 2001, 114(1):107-110.
80. Sinisalo M., Vilpo J., Itala M., Vakevainen M., Taurio J., Aittoniemi J. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine 2007, 26(1):82-87.
81. Morrison V.A. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol 2010, 23(1):145-153.
82. Hamblin A.D., Hamblin T.J. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull 2008, 87:49-62.
83. Takata T., Suzumiya J., Ishikawa T., Takamatsu Y., Ikematsu H., Tamura K. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop 2009, 49(1):9-13.
84. Mazza J.J., Yale S.H., Arrowood J.R., Reynolds C.E., Glurich I., Chyou P.H., et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res 2005, 3(4):214-220.
85. Chow J., Golan Y. Vaccination of solid-organ transplantation candidates. Clin Infect Dis 2009, 49(10):1550-1556.
86. Duchini A., Goss J.A., Karpen S., Pockros P.J. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev 2003, 16(3):357-364.
87. Phillips M.J., Cameron R., Flowers M.A., Blendis L.M., Greig P.D., Wanless I., et al. Post-transplant recurrent hepatitis B viral liver disease. Viral-burden, steatoviral, and fibroviral hepatitis B. Am J Pathol 1992, 140(6):1295-1308.
88. Weikert B.C., Blumberg E.A. Viral infection after renal transplantation: surveillance and management. Clin J Am Soc Nephrol 2008, 3(Supplement_2):S76-S86. 2008.
89. Ballout A., Goffin E., Yombi J.C., Vandercam B. Vaccinations for adult solid organ transplant recipient: current recommendations. Transplant Proc 2005, 37(6):2826-2827.
90. Sester M., Gartner B.C., Girndt M., Sester U. Vaccination of the solid organ transplant recipient. Transplant Rev (Orlando) 2008, 22(4):274-284.
91. Dengler T.J., Zimmermann R., Meyer J., Sack F.U., Girgsdies O., Kubler W.E. Vaccination against tick-borne encephalitis under therapeutic immunosuppression. Reduced efficacy in heart transplant recipients. Vaccine 1999, 17(7-8):867-874.
92. Wingard J.R., Hsu J., Hiemenz J.W. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010, 24(2):257-272.
93. CDC Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Cytotherapy 2001, 3(1):41-54.
94. Ljungman P., Cordonnier C., Einsele H., Englund J., Machado C.M., Storek J., et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009, 44(8):521-526.
95. Hilgendorf I., Jilg W., Einsele H., Greinix H., Halter J., Freund M., et al. Vaccination of haematopoietic stem cell transplant recipients: report from the International Consensus Conference on Clinical Practice in chronic GVHD. Onkologie 2010, 33(Suppl. 6):28.
96. Hilgendorf I., Freund M., Jilg W., Einsele H., Gea-Banacloche J., Greinix H., et al. Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the International Consensus Conference on Clinical Practice in chronic GVHD. Vaccine 2011, 29(16):2825-2833.
97. Parkkali T., Kayhty H., Ruutu T., Volin L., Eskola J., Ruutu P. A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT. Bone Marrow Transplant 1996, 18(5):961-967.
98. Lortan J.E., Vellodi A., Jurges E.S., Hugh-Jones K. Class- and subclass-specific pneumococcal antibody levels and response to immunization after bone marrow transplantation. Clin Exp Immunol 1992, 88(3):512-519.
99. Hammarstrom V., Pauksen K., Azinge J., Oberg G., Ljungman P. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction. Support Care Cancer 1993, 1(4):195-199.
100. Cordonnier C., Labopin M., Chesnel V., Ribaud P., Camara Rde L., Martino R. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine 2010, 28(15):2730-2734.
101. Meisel R., Kuypers L., Dirksen U., Schubert R., Gruhn B., Strauss G., et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 2007, 109(6):2322-2326.